SCHEMBL3579566

SCHEMBL3579566

CCc1c(C(=O)N(C)Cc2ccc3ncccc3c2)[nH]c(C(N)=O)c1S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 4/20 0.43
NAMPT P43490 2/20 0.41
BRD4 O60885 1/20 0.41
BRD3 Q15059 1/20 0.41
SPR P35270 1/20 0.39
AGTR2 P50052 1/20 0.38
USP30 Q70CQ3 1/20 0.37
MAPK1 P28482 2/20 0.36
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 1/20 0.36
TNF P01375 1/20 0.35
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35
BCAT1 P54687 1/20 0.35
HDAC3 O15379 1/20 0.35
TP53 P04637 2/20 0.34
PDE10A Q9Y233 1/20 0.34
THRB P10828 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3586109 0.94 PDK1 (0.42) PDK1NAMPTBRD4BRD3SPR
SCHEMBL3581443 0.92 PDK1 (0.41) PDK1NAMPTBRD4BRD3SPR
SCHEMBL3587158 0.88 PDK1 (0.42) PDK1NAMPTSPRAGTR2USP30
SCHEMBL3574643 0.85 SPR (0.38) PDK1NAMPTBRD4BRD3SPR
SCHEMBL3590189 0.85 SPR (0.38) PDK1NAMPTBRD4BRD3SPR
SCHEMBL3586733 0.84 SPR (0.37) PDK1BRD4BRD3SPRUSP30
SCHEMBL3590262 0.84 SPR (0.38) PDK1BRD4BRD3SPRAGTR2
SCHEMBL3583754 0.82 SPR (0.41) PDK1NAMPTBRD4BRD3SPR
SCHEMBL3590929 0.81 SPR (0.40) PDK1NAMPTBRD4BRD3SPR
SCHEMBL3593677 0.80 NAMPT (0.38) PDK1NAMPTSPRUSP30MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US claimed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP claimed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO claimed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E PDK1 1786/4885NAMPT 76/4885BRD4 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.